Transparency
Transparency
“High Technology” Project
Oncobiomed has been awarded CORFO’s HIGH TECHNOLOGY project, which provides funding totalling up to CLP $896,220,000.
Project 24IAT-272473 entitled ‘Innovation and scaling up of advanced cellular vaccines against cancer’ aims to develop more biologically sophisticated LycellVax and TAPCells formulations, accelerate the transition to clinical studies in colorectal cancer, and facilitate their international commercialisation, thereby reducing patient mortality.
This funding will also enable improvements to infrastructure and production processes in accordance with the standards of the Public Health Institute, as well as strengthening R+D+I capabilities at Oncobiomed through the implementation of advanced technologies and the incorporation of new specialised professionals.
“Human Capital for Innovation” Project
Oncobiomed has been awarded CORFO’s Human Capital for Innovation project, which provides funding totalling up to CLP $40,000,000.
Project 24CH-272306 entitled ‘Development and evaluation of a new manufacturing process for cell culture-based immunotherapies: transition from adhesion platforms to suspension culture with microcarriers for industrial scaling’ aims to strengthen Oncobiomed’s R+D+I capabilities by incorporating a professional specialised in bioprocesses and production under GMP standards to develop the transition from 2D cell cultures to a new 3D suspension production platform.
This will enable us to conduct research into our cell production processes used in the generation of cancer immunotherapies, reduce costs and ensure that products comply with international regulatory requirements, facilitating entry into the global immunotherapy market.
